Eight out of 10 newly diagnosed OSA patients choose oral appliance therapy over CPAP or doing nothing.

Summary: Vivos Therapeutics’ pilot study showed that 79% of newly diagnosed obstructive sleep apnea (OSA) patients preferred oral appliance therapy over CPAP. The study, conducted in multiple dental and ENT offices over seven months, involved 99 patients and demonstrated high acceptance of Vivos’ CARE oral devices. The results highlight the potential of Vivos’ new provider-based marketing and distribution model.

Key Takeaways:

  • High Acceptance Rate: 79% of newly diagnosed adult OSA patients chose oral appliance therapy over CPAP.
  • Pilot Study Scope: The study involved 99 patients across several states with diverse demographics.
  • New Distribution Model: Vivos’ provider-based marketing and distribution model shows promise in increasing patient compliance and treatment acceptance.

Vivos Therapeutics, a maker of oral appliances for obstructive sleep apnea (OSA) treatment, announced positive results from a seven-month, multi-site pilot testing its new provider-based marketing and distribution model. 

On June 12, Vivos announced a new marketing and distribution model under which Vivos is seeking to drive revenue through collaborations with dentists and sleep treatment providers to offer OSA patients a full spectrum of evidence-based treatments for OSA, including Vivos’ US Food and Drug Administration-cleared CARE oral medical devices, oral appliances, and additional adjunctive therapies and methods. 

The pilot program results provide evidence of the potential of this new model, according to a release from Vivos.

The pilot program was conducted over a seven-month period in seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles. A total of 99 patients were seen during the pilot, which was comprised of 76 adults and 23 children under the age of 12.

The results revealed that 79% (60 out of 76) newly diagnosed adult OSA patients chose Vivos’ oral appliance therapy over either continuous positive airway pressure (CPAP) machines or choosing to do nothing, while 5% (4 out of 76) of patients declined all treatment options, and 16% (12 out of 76) patients chose to investigate CPAP as an option before making a final decision. No patients in the pilot program opted for surgical or neurostimulation implant options.

A smaller cohort of 23 pediatric patients with orofacial and developmental abnormalities potentially tied to sleep and breathing disorders such as tongue ties, mouth breathing, malocclusion, and smaller jaws was also evaluated and treated using Vivos orthodontic-guided growth appliances and oral myofunctional therapy.

Mike Skaff, managing director at Seneca Partners, which recently sponsored a $7.5 million investment in Vivos, says in a release, “Throughout the course of the Vivos pilot program, which was part of our due diligence of Vivos, we were impressed by the high patient acceptance rate of Vivos’ treatments’ across all price points and therapy options when compared to CPAP. We are thrilled to be a long-term fundamental investor in Vivos and view these pilot results as compelling validation to our core investment thesis of the higher revenue and gross profit opportunity from the new medical channel.”

Kirk Huntsman, chairman and CEO of Vivos, says in a release, “The message is clear: When Vivos teams up with medical professionals who treat OSA, and when patients are fully informed as to the health risks of untreated OSA and the full range of treatment options available in an open and transparent manner, they overwhelmingly chose Vivos’ CARE oral medical devices.”

Photo caption: Vivos’ mmRNA oral device

File photo